Eczema coxsackium and eczema herpeticum are both viral skin eruptions that strike people who already have atopic dermatitis (eczema), but they are caused by entirely different viruses and carry different levels of danger. Eczema herpeticum is driven by herpes simplex virus and can become life-threatening without prompt antiviral treatment, while eczema coxsackium is caused by an enterovirus, usually coxsackievirus A6, and tends to follow a self-limiting course. Their visual similarity on eczema-damaged skin is exactly what makes distinguishing them so important in the first hours of an outbreak.
Two Different Viruses Targeting the Same Weakness
Both conditions exploit the compromised skin barrier that comes with atopic dermatitis. In healthy skin, viruses have a hard time gaining a foothold because the outer layer acts as a tight physical shield. In eczema, that shield is weakened by inflammation, scratching, and, in many patients, by genetic defects in structural proteins that hold skin cells together. That damaged terrain gives viruses an easier entry point and a wider surface to colonize.
Eczema herpeticum (often abbreviated EH) is caused by herpes simplex virus, usually type 1 (HSV-1), the same virus behind cold sores. When HSV-1 reaches eczema-affected skin, it can spread rapidly across large areas rather than staying confined to the small patch you would expect near the mouth or nose. The virus can enter the bloodstream, leading to viraemia and secondary bacterial infection in the blood, which is why EH is treated as a medical emergency.
Eczema coxsackium (EC) is caused by enteroviruses, most commonly coxsackievirus A6 (CVA6). CVA6 is the same pathogen behind many cases of hand, foot, and mouth disease (HFMD), a common childhood illness. When a child with eczema catches CVA6, instead of the typical scattered spots on hands, feet, and mouth, the rash concentrates in areas already affected by eczema, sometimes becoming far more widespread and severe than ordinary HFMD. In a study that coined the term “eczema coxsackium,” about 55% of children in a CVA6 outbreak had eruptions that were accentuated in their areas of eczematous dermatitis.1PubMed Central. “Eczema coxsackium” and unusual cutaneous findings in an enterovirus outbreak
How They Look on the Skin
The visual overlap between eczema coxsackium and eczema herpeticum is the core clinical problem. Both produce clusters of small, fluid-filled blisters (vesicles) on skin that is already red, dry, and inflamed from eczema. Both tend to affect the face, neck, and trunk. Both can look alarming in a young child. Still, there are differences worth knowing, even if they are not always clear-cut at the bedside.
Eczema herpeticum typically presents with “punched-out” erosions, small, round, uniform-sized ulcers that look as though someone pressed a pencil eraser into the skin. These lesions tend to cluster tightly and may weep or crust over with a yellowish or hemorrhagic scab. The child often appears systemically unwell: fever, irritability, poor feeding, and swollen lymph nodes. Pain is a prominent feature, and the lesions can spread rapidly over 24 to 48 hours.
Eczema coxsackium tends to produce more varied-looking blisters. They may be larger, more irregularly shaped, and scattered across a wider distribution than typical HFMD spots, but they don’t have the same uniform “punched-out” quality of EH. Children with EC may also have oral ulcers and involvement of the palms and soles (hallmarks of classic hand, foot, and mouth disease), which is unusual in EH. Systemic illness in EC is usually milder, though fever and irritability still occur.
Why They Get Confused
During enterovirus outbreaks, children with eczema sometimes arrive at emergency departments with blistering rashes that look strikingly similar to eczema herpeticum. The CVA6-associated outbreak that led researchers to name eczema coxsackium produced an exanthem “potentially more widespread, severe, and varied than classic HFMD that could be confused with bullous impetigo, eczema herpeticum, vasculitis, and primary immunobullous disease.”2PubMed Central. “Eczema coxsackium” and unusual cutaneous findings in an enterovirus outbreak That confusion matters because the treatment paths are completely different.
Eczema coxsackium also needs to be distinguished from conditions like impetigo and varicella, but the eczema herpeticum comparison is the most consequential one clinically.3Indian Journal of Paediatric Dermatology. Eczema Coxsackium: An Unusual Manifestation of Hand, Foot, and Mouth Disease Misdiagnosing EC as EH means a child gets started on intravenous antivirals they don’t need. Misdiagnosing EH as EC means a child with a potentially lethal HSV infection is sent home with supportive care and missed entirely. The stakes tilt heavily toward catching eczema herpeticum when it is present.
Context clues help. If an outbreak of hand, foot, and mouth disease is circulating in the child’s daycare, and the child has oral ulcers and palm or sole involvement, eczema coxsackium rises to the top of the list. If there is no known enterovirus exposure and the blisters have that characteristic punched-out, uniform appearance, eczema herpeticum is more likely. But neither clinical picture is perfectly reliable, which is why lab testing plays such an important role.
How Doctors Tell Them Apart
The gold standard for distinguishing these two conditions is viral testing. For eczema herpeticum, clinicians can swab lesions for HSV using polymerase chain reaction (PCR) or viral culture, both of which detect the virus directly. Serology (blood antibody testing) can support the diagnosis when direct testing is unavailable or delayed; a positive IgM antibody against HSV-1, combined with the clinical picture, has been used to confirm EH in cases where initial confirmatory tests were absent.4PubMed Central. Eczema Herpeticum: Clinical Insights and Pathogenesis Hypotheses on Basolateral Adhesion Proteins
For eczema coxsackium, enterovirus PCR from vesicle fluid, throat swab, or stool sample can identify coxsackievirus. In practice, however, enterovirus testing is not always available in emergency settings or may take days to return. This is why the default clinical approach leans cautious: if eczema herpeticum cannot be ruled out, most clinicians will start antiviral therapy while waiting for results, because the downside of missing EH is far worse than the downside of a few unnecessary doses of acyclovir.
What Makes Eczema Herpeticum More Dangerous
Eczema herpeticum carries a risk of serious complications that eczema coxsackium does not. HSV can spread beyond the skin into the bloodstream, and secondary bacterial sepsis is a recognized threat. In children, first episodes of herpes infection tend to be the most severe, and the condition requires systemic antiviral treatment, typically intravenous acyclovir for severe cases.5BMJ Journals. Fifteen-minute consultation: eczema herpeticum in a child Without treatment, EH can progress rapidly. Involvement of the eyes can threaten vision, and widespread disease in immunocompromised patients or neonates can be fatal.
The bacterial angle adds another layer of risk. An imbalance in the skin microbiome, specifically an overgrowth of Staphylococcus aureus, appears to assist HSV by creating a more permissive environment for viral infection through secreted toxins.6PubMed. Eczema herpeticum in atopic dermatitis This means that children with eczema who are already colonized with staph bacteria on their skin may face a double hit when HSV arrives.
Eczema coxsackium, by contrast, is usually self-limiting. It looks dramatic and can cause significant discomfort, but it resolves on its own within one to two weeks. The blisters may desquamate (peel), and some children experience temporary nail shedding (onychomadesis) weeks after the illness, a well-known aftermath of coxsackievirus infection. Serious systemic complications from EC are rare.
Why Some People With Eczema Are More Vulnerable to EH
Not everyone with atopic dermatitis develops eczema herpeticum when exposed to HSV. Research over the past two decades has identified several factors that push certain patients into higher risk territory, and most of them trace back to the skin’s ability to defend itself against viral invasion.
One of the strongest genetic risk factors involves mutations in the gene for filaggrin, a protein critical for building the outermost barrier of the skin. A specific mutation called R501X was found at dramatically elevated rates in patients with eczema herpeticum. In one analysis, roughly a quarter of patients with EH carried this mutation, and carrying both the R501X and a second filaggrin mutation (2282del4) raised risk further still, an association seen in both European American and African American populations.7Journal of Allergy and Clinical Immunology. Filaggrin mutations that confer risk of atopic dermatitis confer greater risk for eczema herpeticum Animal studies have reinforced this link: filaggrin-deficient mice develop spreading skin lesions when exposed to vaccinia virus (a relative of smallpox virus), while normal mice do not, suggesting that a weakened physical barrier directly enables viral spread across the skin surface.8Journal of Allergy and Clinical Immunology. Filaggrin null mutations are associated with increased severity of atopic dermatitis eczema herpeticum
Beyond the physical barrier, the immune defenses embedded in the skin also play a role. The skin produces antimicrobial peptides, small molecules that act like a built-in antibiotic and antiviral system. Patients who develop eczema herpeticum have significantly lower levels of one of these peptides, cathelicidin, compared with eczema patients who don’t develop EH.9PubMed Central. Cathelicidin Deficiency Predisposes to Eczema Herpeticum Other antimicrobial peptides, including human beta-defensins 2 and 3, are also reduced in eczema skin compared with other inflammatory skin conditions, along with dermcidin, an antimicrobial molecule normally found in sweat.10PubMed Central. Antimicrobial peptides, skin infections, and atopic dermatitis
On top of the barrier and antimicrobial peptide deficits, the immune signaling in eczema-prone skin is skewed in ways that make antiviral defense harder. There is an overproduction of certain inflammatory signals that drive the allergic-type inflammation of eczema, while the interferon pathways that normally mobilize the body’s antiviral response are suppressed. Immune cells like natural killer cells and certain types of dendritic cells also show reduced function.11PubMed. Eczema Herpeticum: Clinical and Pathophysiological Aspects The result is skin that is simultaneously hyper-inflamed in the wrong direction (allergic) and under-defended in the right direction (antiviral).
Treatment Differences That Matter
This is where the distinction between the two conditions becomes most consequential. Eczema herpeticum requires antiviral medication. Acyclovir (or valacyclovir) is the mainstay, given intravenously in severe cases or orally in milder presentations. Treatment should start as soon as EH is suspected, without waiting for lab confirmation, because delays allow the virus to spread further. Hospitalization is common for young children, patients with widespread disease, or anyone who appears systemically unwell.
Eczema coxsackium has no specific antiviral treatment. Management is supportive: pain control, keeping the skin clean, maintaining hydration, and managing the underlying eczema flare. The illness runs its course, and the blisters heal on their own. Antibiotics are only needed if there is clear secondary bacterial infection of the blistered skin.
A recurring question in eczema herpeticum management is whether topical corticosteroids, the backbone of daily eczema care, should be stopped during an active EH episode. The concern is that suppressing the local immune response might help HSV spread further. A study of hospitalized children with eczema herpeticum found that using topical corticosteroids on the first day of hospitalization was not associated with longer hospital stays, and the same was true for topical calcineurin inhibitors (another class of anti-inflammatory eczema treatment).12PubMed. Topical corticosteroids and hospital length of stay in children with eczema herpeticum This doesn’t mean topical steroids are proven safe during EH, and clinicians still weigh the decision case by case, but the fear that they automatically worsen the infection appears overstated based on available data.
What Parents Should Watch For
For parents of children with eczema, the practical takeaway comes down to pattern recognition. A flare that looks different from the usual eczema, particularly one that involves small, clustered, fluid-filled blisters appearing rapidly on already inflamed skin, warrants a same-day medical evaluation. If the child has a fever, seems unusually unwell, or the blisters have that distinctive punched-out appearance, eczema herpeticum should be excluded before anything else.
If hand, foot, and mouth disease is circulating at school or daycare, and your child’s eczema suddenly worsens with widespread blistering, eczema coxsackium is a strong possibility. Still, the only way to be certain is a clinical assessment and, ideally, viral testing. Parents should not try to make the call themselves because the visual overlap is too great and the consequences of guessing wrong are too uneven.
One practical detail that catches some parents off guard: children with eczema coxsackium can remain infectious for longer than the illness looks active. Good hand hygiene is important for preventing spread, and stools can carry the enterovirus for up to a month after the acute illness has resolved. Children typically need to stay home from school until all blisters have fully dried.
Recurrence and Long-Term Outlook
Eczema herpeticum can recur. Because herpes simplex virus establishes lifelong latency in nerve cells, it can reactivate at any time, especially during periods when the immune system is suppressed or the skin barrier is particularly compromised. Recurrent episodes tend to be milder than the initial one, but they still require antiviral treatment. Patients with a history of EH are generally counseled to have a supply of oral acyclovir on hand and to start it at the first sign of a recurrence.
Eczema coxsackium does not recur in the same way because enteroviruses do not establish latency. Once the body clears the virus and builds immunity, that particular strain should not cause the same problem again. However, there are many different enterovirus serotypes, so reinfection with a different strain is possible in theory, though repeated episodes of eczema coxsackium in the same patient are uncommon in practice.
Children who experience either condition often see their underlying eczema flare during and after the viral episode, sometimes more severely than before. Managing that post-viral eczema exacerbation with appropriate moisturizers and topical anti-inflammatory therapy is an important part of recovery that sometimes gets overshadowed by the acute drama of the viral illness itself.
The Newer Condition in an Older Framework
Eczema herpeticum has been recognized for decades and has a well-developed body of research behind it, including genetic studies, immunological profiling, and treatment trials. Eczema coxsackium, by comparison, was only named in 2013, when a CVA6 outbreak in a pediatric population led clinicians to formally describe the pattern of enteroviral rash concentrating in eczematous skin.13PubMed Central. “Eczema coxsackium” and unusual cutaneous findings in an enterovirus outbreak That study included 80 patients, with a median age of a year and a half, and was the first to give the phenomenon a clinical name.
Because eczema coxsackium is a relatively new diagnostic category, there is far less published literature on its risk factors, immune mechanisms, and long-term outcomes compared with eczema herpeticum. It remains unclear whether the same filaggrin mutations and antimicrobial peptide deficiencies that predispose to EH also increase susceptibility to EC, or whether EC is more of an equal-opportunity complication in anyone with active eczema who encounters CVA6. Filling that gap would help clinicians understand which children with eczema need to be most vigilant during enterovirus season and whether any preventive strategies, beyond avoiding exposure, could reduce risk.